text:
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.
Prevention and control of nausea and vomiting (emesis) (N&V) are paramount in the treatment of cancer patients. N&V can result in serious metabolic derangements, nutritional depletion and anorexia, deterioration of patients' physical and mental status, esophageal tears, fractures, wound dehiscence, withdrawal from potentially useful and curative antineoplastic treatment, and degeneration of self-care and functional ability. (See Table 1 for criteria on grading severity.) Despite advances in pharmacologic and nonpharmacologic management, N&V remain two of the more distressing and feared side effects to cancer patients and their families, and incidence may be underestimated by physicians and nurses.[1,2,3,4,5]
In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed. The evidence and application to practice related to children may differ significantly from information related to adults. When specific information about the care of children is available, it is summarized under its own heading.
Nausea is a subjective phenomenon of an unpleasant, wavelike sensation experienced in the back of the throat and/or the epigastrium that may culminate in vomiting (emesis). Vomiting is the forceful expulsion of the contents of the stomach, duodenum, or jejunum through the oral cavity. Retching is gastric and esophageal movements of vomiting without expulsion of vomitus and is also referred to as dry heaves.
Various classifications of N&V have been used,[1,6] including acute, delayed, late or persistent, chronic, anticipatory, breakthrough, or refractory, as well as distinctions related to type of treatment (e.g., chemotherapy induced or radiation induced) and clinical course of disease (e.g., advanced or terminal disease).[7,8] Despite this variety, the most commonly described types of N&V are acute, delayed, and anticipatory chemotherapy-induced N&V and chronic N&V in advanced cancer patients. Although there are no standard definitions, the following are commonly used to classify the different types.
Progress has been made in understanding the neurophysiologic mechanisms that control nausea and vomiting (emesis) (N&V). Both are controlled or mediated by the central nervous system but by different mechanisms. Nausea is mediated through the autonomic nervous system. Vomiting results from the stimulation of a complex reflex that is coordinated by a putative true vomiting center, which may be located in the dorsolateral reticular formation near the medullary respiratory centers. The vomiting center presumably receives convergent afferent stimulation from several central neurologic pathways, including the following:[1,2]
The CTZ is located in the area postrema, one of the circumventricular regions of the brain on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle. Unlike vasculature within the blood-brain diffusion barrier, the area postrema is highly vascularized with fenestrated blood vessels, which lack tight junctions (zonae occludentes) between capillary endothelial cells. The CTZ is anatomically specialized to readily sample elements present in the circulating blood and cerebrospinal fluid (CSF).[3,4]
Currently, evidence indicates that acute emesis following chemotherapy is initiated by the release of neurotransmitters from cells that are susceptible to the presence of toxic substances in the blood or CSF. Area postrema cells in the CTZ and enterochromaffin cells within the intestinal mucosa are implicated in initiating and propagating afferent stimuli that ultimately converge on central structures corresponding to a vomiting center. The relative contribution from these multiple pathways culminating in N&V symptoms is complex and is postulated to account for the variable emetogenicity (intrinsic emetogenicity and mitigating factors [i.e., dosage, administration route, and exposure duration]) and emetogenic profile (i.e., time to onset, symptom severity, and duration) of agents.
Not all cancer patients will experience nausea, vomiting (emesis), or both. The most common causes are emetogenic chemotherapy drugs and radiation therapy to the gastrointestinal (GI) tract, liver, or brain. Several patient characteristics have also been identified. These include incidence and severity of nausea and vomiting (N&V) during past courses of chemotherapy, history of chronic alcohol use, age, and gender. Patients with poor control of N&V during prior chemotherapy cycles are likely to experience N&V in subsequent cycles. N&V is less likely in patients with a history of chronic high intake of alcohol [1] and more likely in women [2,3] and in patients younger than 50 years.[2]
Other possible causes include fluid and electrolyte imbalances such as hypercalcemia, volume depletion, or water intoxication; tumor invasion or growth in the GI tract, liver, or central nervous system, especially the posterior fossa; constipation; certain drugs such as opioids; infection or septicemia; or uremia. The psychological variables of state anxiety (level of anxiety during chemotherapy infusions) and pretreatment expectations for N&V (self-fulfilling prophecy) have also been investigated as predictors of posttreatment nausea.[4,5,6,7,8,9] At present, studies have found mixed results that vary due to different research methods. Better designed studies, however, have found state anxiety and patient expectations for nausea to be predictors of posttreatment nausea, even after controlling for known physiological predictors (susceptibility to nausea during pregnancy and motion sickness) and emetogenic potential of the chemotherapy drugs.[6,7,8,10,11] It is important to note, however, that patients' fears and expectations about chemotherapy can be variable and change over time.[12] In a longitudinal study,[12] patients' anticipatory fears of vomiting decreased significantly from pretreatment to a period 3 to 6 months later, particularly when their chemotherapy included antiemetic medications.
Clinicians treating N&V must be alert to all potential causes and factors, especially in cancer patients who may be receiving combinations of several treatments and medications. (Refer to the PDQ summary on Pain for more information on opioid-induced N&V.)
The prevalence of anticipatory nausea and vomiting (emesis) (ANV) has varied, owing to changing definitions and assessment methods.[1] However, anticipatory nausea appears to occur in approximately 29% of patients receiving chemotherapy (about one of three patients), while anticipatory vomiting appears to occur in 11% of patients (about one of ten patients).[2] With the introduction of new pharmacologic agents (5-HT3 receptor antagonists), it was anticipated that the prevalence of ANV might decline; however, studies have shown mixed results. One study found a lower incidence of ANV,[3] and three studies found comparable incidence rates.[2,4,5] It appears that the 5-HT3 agents reduce postchemotherapy vomiting but not postchemotherapy nausea,[2,5] and the resulting impact on ANV is unclear.
Classical Conditioning
Although other theoretical mechanisms have been proposed,[6] ANV appears to be best explained by classical conditioning (also known as Pavlovian or respondent conditioning).[7] In classical conditioning, a previously neutral stimulus (e.g., smells of the chemotherapy environment) elicits a conditioned response (e.g., ANV) after a number of prior pairings or learning trials. In cancer chemotherapy, the first few chemotherapy infusions are the learning trials. The chemotherapy drugs are the unconditioned stimuli that elicit postchemotherapy nausea and vomiting (N&V) (in some patients). The drugs are paired with a variety of other neutral, environmental stimuli (e.g., smells of the setting, oncology nurse, chemotherapy room). These previously neutral stimuli then become conditioned stimuli and elicit ANV in future chemotherapy cycles. ANV is not an indication of psychopathology but is rather a learned response that, in other life situations (e.g., food poisoning), results in adaptive avoidance. A variety of correlational studies provide empirical support for classical conditioning. For example, the prevalence of ANV prior to any chemotherapy is very rare, and few patients ever experience ANV without prior postchemotherapy nausea.[8] Also, most studies have found (1) a higher probability of ANV with increasing numbers of chemotherapy infusions and (2) the intensity of ANV increasing as patients get closer to the actual time of their infusion.[9] In one experimental study, it was shown that a novel beverage could become a conditioned stimulus to nausea when paired with several chemotherapy treatments.[10]
Variables Correlated with ANV
Many variables have been investigated as potential factors that correlate with the incidence of ANV in hopes of developing a list of risk factors. There is currently no agreement on which factors predict ANV. A patient with fewer than three of the first eight characteristics listed below, however, is unlikely to develop ANV, and screening following the first chemotherapy infusion could identify those patients at increased risk.[11]
Variables Found to Correlate With ANV
Treatment of ANV
Antiemetic drugs do not seem to control ANV once it has developed;[2] however, a variety of behavioral interventions have been investigated.[19] These include progressive muscle relaxation with guided imagery,[20] hypnosis,[21] systematic desensitization,[22] electromyography and thermal biofeedback,[23] and distraction via the use of video games.[24,25] Progressive muscle relaxation with guided imagery, hypnosis, and systematic desensitization has been studied the most and is the recommended treatment. Referral to a psychologist or other mental health professional with specific training and experience in working with cancer patients is recommended when ANV is identified. The earlier ANV is identified, the more likely treatment will be effective; thus, early screening and referral are essential. In addition, physicians and nurses underestimate the incidence of chemotherapy-induced nausea and vomiting.[26][Level of evidence: II]
Acute Nausea and Vomiting (Emesis) (N&V)
In addition to emetogenic potential, the dose and schedule used are also extremely important factors. For example, a drug with a low emetogenic potential given in high doses may cause a dramatic increase in the potential to induce N&V. Standard doses of cytarabine rarely produce N&V, but these are often seen with high doses of this drug. Another factor to consider is the use of drug combinations. Because most patients receive combination chemotherapy, the emetogenic potential of all of the drugs combined and individual drug doses needs to be considered.
Delayed N&V
Delayed (or late) N&V occurs more than 24 hours after chemotherapy administration. Delayed N&V is associated with cisplatin, cyclophosphamide, and other drugs (e.g., doxorubicin and ifosfamide) given at high doses or given on 2 or more consecutive days.
Antiemetic agents are the most common intervention in the management of treatment-related nausea and vomiting (emesis) (N&V). The basis for antiemetic therapy is the neurochemical control of vomiting. Although the exact mechanism is not well understood, peripheral neuroreceptors and the chemoreceptor trigger zone (CTZ) are known to contain receptors for serotonin, histamine (H1 and H2), dopamine, acetylcholine, opioids, and numerous other endogenous neurotransmitters.[1,2] Many antiemetics act by competitively blocking receptors for these substances, thereby inhibiting stimulation of peripheral nerves at the CTZ and possibly at the vomiting center. Most drugs with proven antiemetic activity can be categorized into one of the following groups:
Although all routes of administration are listed for each of the following drugs, the intramuscular (IM) route should be used only when no other access is available. IM delivery is painful, is associated with erratic absorption of drug, and may lead to sterile abscess formation or fibrosis of the tissues. This is particularly important when more than one or two doses of a drug are to be given.
Phenothiazines act on dopaminergic receptors at the CTZ, possibly at other central nervous system (CNS) centers, and peripherally. With the exception of thioridazine, many phenothiazines possess antiemetic activity, including chlorpromazine given in the 10- to 50-mg dose range orally, IM, intravenously (IV), and rectally (pediatric dose for patients >12 years: 10 mg every 6–8 hours; for patients <12 years: 5 mg every 6–8 hours); thiethylperazine given in the 5- to 10-mg dose range orally, IM, and IV; and perphenazine. The primary consideration in selecting among phenothiazines are differences in their adverse effect profiles, which substantially correlate with their structural classes. Generally, aliphatic phenothiazines (e.g., chlorpromazine, methotrimeprazine) produce sedation and anticholinergic effects, while piperazines (e.g., prochlorperazine, thiethylperazine, perphenazine, fluphenazine) are associated with less sedation but greater incidence of extrapyramidal reactions (EPRs).
Prochlorperazine is perhaps the most frequently (and empirically) used antiemetic and, in low doses, is generally effective in preventing nausea associated with radiation therapy and in treating N&V attributed to very low to moderately emetogenic chemotherapeutic drugs. Prochlorperazine is a phenothiazine and can be given orally, IM, IV, and rectally. It is usually given in the 10- to 50-mg dose range (pediatric dose for children who weigh >10 kg or who are >2 years: orally or rectally, 0.4 mg/kg/dose tid–qid; or IM, 0.1–0.15 mg/kg/dose tid–qid, maximum 40 mg/d). Higher prochlorperazine doses (e.g., 0.2–0.6 mg/kg/dose) are also given IV for patients receiving chemotherapy with high emetogenic potential.[3];[4][Level of evidence: I] Phenothiazines may be of particular value in treating patients who experience delayed N&V (postacute phase symptoms) on cisplatin regimens.[5][Level of evidence: I]
As with other dopaminergic antagonists, the most common side effects of prochlorperazine are EPRs (acute dystonias, akathisias, neuroleptic malignant syndrome [uncommon], and rarely, akinesias and dyskinesias) and sedation. Marked hypotension may also result if IV prochlorperazine is administered rapidly at high doses. Administration over at least 30 minutes appears adequate to prevent hypotensive episodes.[6,7,8]
Droperidol and haloperidol
Droperidol and haloperidol represent another class of dopaminergic (D2 subtype) receptor antagonists that are structurally and pharmacologically similar to the phenothiazines. While droperidol is used primarily as an adjunct to anesthesia induction, haloperidol is indicated as a neuroleptic antipsychotic drug; however, both agents have some antiemetic activity. Droperidol is administered IM or IV, typically from 1 to 2.5 mg every 2 to 6 hours, but higher doses (up to 10 mg) have been safely given.[9,10] Haloperidol is administered IM, IV, or orally, typically from 1 to 4 mg every 2 to 6 hours.[11] Results of a small, uncontrolled, open-label study showed some efficacy for haloperidol in palliative care patients.[12] Both agents may produce EPRs, akathisia, hypotension, and sedation.
Dopamine 2 Antagonists
Metoclopramide is a substituted benzamide, which, prior to the introduction of serotonin (5-HT3) receptor antagonists, was considered the most effective single antiemetic agent against highly emetogenic chemotherapy such as cisplatin. Although metoclopramide is a competitive antagonist at dopaminergic (D2) receptors, it is most effective against acute vomiting when given IV at high doses (e.g., 0.5–3 mg/kg/dose), probably because it is a weak competitive antagonist (relative to other serotonin antagonists) at 5-HT3 receptors. It may act on the CTZ and the periphery. Metoclopramide also increases lower esophageal sphincter pressure and enhances the rate of gastric emptying, which may factor into its overall antiemetic effect. It can be administered IV at the U.S. Food and Drug Administration (FDA)–approved dose of 1 to 2 mg/kg every 2 hours (or less frequently) for three to five doses. Metoclopramide has also been safely given by IV bolus injection at higher single doses (up to 6 mg/kg) and by continuous IV infusion, with or without a loading bolus dose, with efficacy comparable to multiple intermittent dosing schedules.[13,14,15]
Metoclopramide is associated with akathisia and dystonic extrapyramidal effects; akathisia is seen more frequently in patients older than 30 years, and dystonic extrapyramidal effects are seen more commonly in patients younger than 30 years. Diphenhydramine, benztropine mesylate, and trihexyphenidyl are commonly used prophylactically or therapeutically to pharmacologically antagonize EPRs.[7,16] While cogwheeling rigidity, acute dystonia, and tremor are responsive to anticholinergic medications, akathisia—the subjective sense of restlessness or inability to sit still—is best treated by the following:
5-HT3 Receptor Antagonists
Four serotonin receptor antagonists—ondansetron, granisetron, dolasetron, and palonosetron—are available in the United States. Tropisetron, while not approved by the FDA, is available internationally. Agents in this class are thought to prevent N&V by preventing serotonin, which is released from enterochromaffin cells in the gastrointestinal (GI) mucosa, from initiating afferent transmission to the CNS via vagal and spinal sympathetic nerves.[17] The 5-HT3 receptor antagonists may also block serotonin stimulation at the CTZ and other CNS structures.
Several studies have demonstrated that ondansetron produces an antiemetic response that equals or is superior to high doses of metoclopramide, but ondansetron has a superior toxicity profile compared with dopaminergic antagonist agents.[18,19,20,21,22][Level of evidence: I][23,24] Ondansetron (0.15 mg/kg) is given IV 15 to 30 minutes prior to chemotherapy and is repeated every 4 hours for two additional doses. Alternatively, for patients older than 18 years, a large multicenter study determined that a single 32-mg dose of ondansetron is more effective in treating cisplatin-induced N&V than a single 8-mg dose and is as effective as the standard regimen of three doses at 0.15 mg/kg given every 4 hours starting 30 minutes before chemotherapy.[25][Level of evidence: I] A single-center retrospective chart review has reported ondansetron-loading doses of 16 mg/m2 (maximum, 24 mg) IV to be safe in infants, children, and adolescents.[26]
Currently, the oral and injectable ondansetron formulations are approved for use without dosage modification in patients older than 4 years, including elderly patients and patients with renal insufficiency. Oral ondansetron is given 3 times daily starting 30 minutes before chemotherapy and continuing for up to 2 days after chemotherapy is completed. Patients older than 12 years should receive 4 mg per dose. Ondansetron is not approved for use in children younger than 4 years. Ondansetron clearance is diminished in patients with severe hepatic insufficiency; therefore, such patients should receive a single injectable or oral dose no higher than 8 mg. There is currently no information available evaluating the safety of repeated daily ondansetron doses in patients with hepatic insufficiency. Other effective dosing schedules such as a continuous IV infusion (e.g., 1 mg/h for 24 h) or oral administration have also been evaluated.[25]
The major adverse effects include headache (which can be treated with mild analgesics), constipation or diarrhea, fatigue, dry mouth, and transient asymptomatic elevations in liver function tests (alanine and aspartate transaminases), which may be related to concurrent cisplatin administration.[27] Ondansetron has been etiologically implicated in a few case studies involving thrombocytopenia, renal insufficiency, and thrombotic events.[28] In addition, a few case reports have implicated ondansetron in causing EPRs. However, it is not clear in some cases whether the events described were in fact EPRs; in other reports, the evidence is confounded by concurrent use of other agents that are known to produce EPRs. Nevertheless, the greatest advantage of serotonin receptor antagonists over dopaminergic receptor antagonists is that they have fewer adverse effects. Despite prophylaxis with ondansetron, many patients receiving doxorubicin, cisplatin, or carboplatin will experience acute and delayed-phase N&V.[29][Level of evidence: II] A randomized, double-blind, placebo-controlled trial suggests that the addition of aprepitant, a neurokinin-1 (NK-1) receptor antagonist, may mitigate N&V.[30][Level of evidence: I] The optimal dose of aprepitant may be 125 mg on day 1 followed by 80 mg on days 2 to 5.[31][Level of evidence: I]
Granisetron has demonstrated efficacy in preventing and controlling N&V at a broad range of doses (e.g., 10–80 µg/kg and empirically, 3 mg/dose). In the United States, granisetron injection, transdermal patch, and oral tablets are approved for initial and repeat prophylaxis for patients receiving emetogenic chemotherapy, including high-dose cisplatin. Granisetron is pharmacologically and pharmacokinetically distinct from ondansetron; however, clinically it appears equally efficacious and equally safe.[32,33,34,35][Level of evidence: I] Both granisetron formulations are given before chemotherapy, as either a single IV dose of 10 µg/kg (0.01 mg/kg) or 1 mg orally every 12 hours.
Both granisetron formulations and ondansetron injection share the same indication against highly emetogenic chemotherapy. In contrast, the oral ondansetron formulation has been approved only for use against N&V associated with moderately emetogenic chemotherapy.
Currently, granisetron injection is approved for use without dosage modification in patients older than 2 years, including elderly patients and patients with hepatic and renal insufficiency. Oral granisetron has not yet been approved for use in pediatric patients.
Both oral and injection formulations of dolasetron are indicated for the prevention of N&V associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses. Oral dolasetron should be dosed as 100 mg within 1 hour before chemotherapy. Dolasetron should be given IV or orally at 1.8 mg/kg as a single dose approximately 30 minutes before chemotherapy.
The effectiveness of oral dolasetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) has been proven in a large randomized, double-blind, comparative trial of 399 patients.[36][Level of evidence: I] Oral dolasetron was administered in the range of 25 to 200 mg 1 hour prior to chemotherapy. The other study arm consisted of oral ondansetron (8 mg) administered 1.5 hours before chemotherapy and every 8 hours after chemotherapy for a total of three doses. Complete response (CR) rates improved with increasing doses of dolasetron. Both dolasetron 200 mg and ondansetron had significantly higher CR rates as compared with dolasetron 25 or 50 mg. (CR was defined as no emetic episodes and no use of escape antiemetic medications.) Dolasetron injection has also been proven effective in the prevention of CINV.[37][Level of evidence: I]
Palonosetron is a 5-HT3 receptor antagonist (second generation) that has antiemetic activity at both central and gastrointestinal sites. In comparison to the older 5-HT3 receptor antagonists, it has a higher binding affinity to the 5-HT3 receptors, a higher potency, a significantly longer half-life (approximately 40 hours, four to five times longer than that of dolasetron, granisetron, or ondansetron), and an excellent safety profile.[38][Level of evidence: I] A dose-finding study demonstrated that the effective dose was 0.25 mg or higher.[38] In two large studies of patients receiving moderately emetogenic chemotherapy, CR (no emesis, no rescue) was significantly improved in the acute and the delayed period for patients who received 0.25 mg of palonosetron alone compared with either ondansetron or dolasetron alone.[39];[40][Level of evidence: I] Dexamethasone was not given with the 5-HT3 receptor antagonists in these studies, and it is not yet known whether the differences in CR would persist if dexamethasone was used. In another study,[41][Level of evidence: I] 650 patients receiving highly emetogenic chemotherapy (cisplatin ≥60 mg/m2) also received either dexamethasone and one of two doses of palonosetron (0.25 mg or 0.75 mg) or dexamethasone and ondansetron (32 mg). Single-dose palonosetron was as effective as ondansetron in preventing acute CINV with dexamethasone pretreatment; it was significantly more effective than ondansetron throughout the 5-day postchemotherapy period. In an analysis of the patients in the above studies who received repeated cycles of chemotherapy, one author [42] reported that the CR rates for both acute and delayed CINV were maintained with single IV doses of palonosetron without concomitant corticosteroids. These data will require further review.
On the basis of the studies described above, palonosetron was approved by the FDA in July 2003 for the prevention of acute N&V associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed N&V associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. One randomized, double-blind, phase III trial compared palonosetron plus dexamethasone with granisetron plus dexamethasone for the prevention of CINV in patients receiving highly emetogenic chemotherapy. Palonosetron was equivalent to granisetron in the acute phase (first 24 hours) and better than granisetron in the delayed phase (24–120 hours), with a comparable safety profile for the two treatments.[43][Level of evidence: I]
Comparison of agents
Clinicians should note that studies suggest that there are no major differences in efficacy or toxicity of the three first-generation 5-HT3 receptor antagonists (dolasetron, granisetron, and ondansetron) in the treatment of acute CINV. These three agents are equivalent in efficacy and toxicity when used in appropriate doses.[44];[45,46,47][Level of evidence: I] Although these agents have been shown to be effective in the first 24 hours postchemotherapy (acute phase), they have not been demonstrated to be effective in days 2 to 5 postchemotherapy (delayed phase).[29,48,49]
Palonosetron, the second-generation 5-HT3 receptor antagonist, has been approved for the control of delayed emesis for patients receiving moderately emetogenic chemotherapy.[39];[40][Level of evidence: I]
Despite the use of both first-generation and second-generation 5-HT3 receptor antagonists, the control of acute CINV, and especially delayed N&V, is suboptimal, and there is considerable opportunity for improvement with either the addition or substitution of new agents in current regimens.[29][Level of evidence: II];[50][Level of evidence: I][48,49]
Substance P Antagonists (NK-1 Receptor Antagonists)
The initial clinical studies using the NK-1 receptor antagonists [51,52,53][Level of evidence: I][54] demonstrated that the addition of an NK-1 receptor antagonist (CP-122,721, CJ-11,794, MK-0869 [aprepitant]) to a 5-HT3 receptor antagonist plus dexamethasone prior to cisplatin chemotherapy improved the control of acute emesis compared with a 5-HT3 receptor antagonist plus dexamethasone and improved the control of delayed emesis compared with placebo. In addition, as a single agent, aprepitant (MK-0869) had an effect similar to that of ondansetron on cisplatin-induced acute emesis but was superior in the control of delayed emesis. Subsequent studies [55,56][Level of evidence: I] showed that the combination of aprepitant and dexamethasone was similar to a 5-HT3 receptor antagonist plus dexamethasone in controlling acute emesis but was inferior in controlling acute emesis compared with triple therapy (aprepitant, 5-HT3 receptor antagonist, and dexamethasone). These studies also confirmed the improvement of delayed emesis with the use of aprepitant compared with placebo. Two studies [31,57][Level of evidence: I] have also shown an improvement in cisplatin-induced delayed emesis with the combination of aprepitant and dexamethasone compared with dexamethasone alone, with the improvement maintained over repeat cycles of cisplatin chemotherapy.
In two randomized, double-blind, parallel, multicenter, controlled studies (520 patients in each study), patients received cisplatin (≥70 mg/m2) and were randomly assigned to receive either standard therapy with a 5-HT3 receptor antagonist (ondansetron) and dexamethasone prechemotherapy and dexamethasone postchemotherapy (days 2–4) or standard therapy plus aprepitant prechemotherapy and on days 2 and 3 postchemotherapy.[30,58][Level of evidence: I] The CR (no emesis, no rescue) of the aprepitant group in both studies was significantly higher in both the acute period (83%–89%) and the delayed period (68%–75%), compared with the CR of the standard therapy group in the acute period (68%–78%) and delayed period (47%–56%). Nausea was improved in the aprepitant group for some, but not all of the various specific measures of nausea.[30] The studies discussed above formed the basis for the approval of aprepitant by the FDA in March 2003. In combination with other antiemetics, aprepitant is indicated for the prevention of acute and delayed N&V associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. An additional study confirmed the efficacy of aprepitant in the delayed period, when it was compared with ondansetron.[59][Level of evidence: I]
All of the initial studies using aprepitant were conducted in patients receiving highly emetogenic chemotherapy such as cisplatin-based chemotherapy regimens. Subsequently, one group [60][Level of evidence: I] presented a study on the use of aprepitant in 862 breast cancer patients receiving moderately emetogenic chemotherapy (e.g., cyclophosphamide, doxorubicin). Two regimens were compared. Because the chemotherapy was moderately emetogenic, steroids were omitted from both arms, as illustrated in Table 2.
There was a significant improvement in CR (no emesis, no rescue) in the 24 hours after chemotherapy in the patients receiving aprepitant; however, there was no significant improvement in CR on days 2 to 5 in the postchemotherapy period when aprepitant alone was compared with ondansetron alone. The overall (days 1–5) CR was significantly improved for the aprepitant-containing regimen, most likely because of the improvement in the first 24 hours. The control of nausea in moderately emetogenic chemotherapy was not improved with the use of aprepitant without steroids on days 2 and 3 postchemotherapy. These results were consistent for multiple cycles of chemotherapy.[61] The role of aprepitant in moderately emetogenic chemotherapy remains undetermined. One open-label study demonstrated that in the 5 days postchemotherapy, aprepitant in combination with palonosetron and dexamethasone is safe and highly effective in preventing CINV in patients receiving moderately emetogenic chemotherapy.[62][Level of evidence: II] Another study reported that aprepitant combined with ondansetron and dexamethasone provided superior efficacy in the prevention of acute and delayed CINV in a broad range of patients receiving moderately emetogenic chemotherapy (both anthracycline-cyclophosphamide regimens and nonanthracycline-cyclophosphamide regimens).[63] It is not known whether aprepitant is necessary in all moderately emetogenic regimens.
A randomized phase III trial evaluated the use of aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors who were receiving 5-day cisplatin combination chemotherapy.[64] There was a significant reduction in the amount of emesis and use of rescue medications with the use of aprepitant. This study suggests that aprepitant may be useful in the prevention of CINV in multiday chemotherapy regimens.
Fosaprepitant dimeglumine, a water-soluble, phosphorylated analog of aprepitant, is rapidly converted to aprepitant after IV administration.[65] Fosaprepitant (115 mg) was approved by the FDA as an alternative to the 125-mg oral aprepitant dose on day 1 of a 3-day regimen. As demonstrated in a randomized, double-blind study of patients receiving cisplatin chemotherapy, single-dose IV fosaprepitant (150 mg) given with ondansetron and dexamethasone was noninferior to the standard 3-day dosing of oral aprepitant in preventing CINV.[66]
Casopitant is a neurokinin-1 receptor antagonist that is being developed as a potential treatment for CINV and postoperative N&V.[67] Phase III clinical trials have been completed, demonstrating an improvement in chemotherapy-induced emesis when casopitant is added to the antiemetic combination of ondansetron and dexamethasone in patients receiving highly emetogenic chemotherapy [68,69][Level of evidence: I] or moderately emetogenic chemotherapy.[70] Applications to the FDA for these indications have been made and are pending. Casopitant appears to be very similar to aprepitant in terms of efficacy in controlling CINV. The current studies suggest that casopitant is effective as 1-day oral or IV dosing prior to chemotherapy, compared with the FDA-approved 3-day dosing of aprepitant.
Steroids are sometimes used as single agents against mildly to moderately emetogenic chemotherapy but are more often used in antiemetic drug combinations.[71][Level of evidence: II];[72,73][Level of evidence: I] Their antiemetic mechanism of action is not fully understood, but they may affect prostaglandin activity in the brain. Clinically, steroids quantitatively decrease or eliminate episodes of N&V and may improve patients' mood, thus producing a subjective sense of well-being or euphoria (although they also can cause depression and anxiety). In combination with high-dose metoclopramide, steroids may mitigate adverse effects such as the frequency of diarrheal episodes.
Steroids are often given IV before chemotherapy and may or may not be repeated. Dosages and administration schedules are selected empirically. Dexamethasone is often the treatment of choice in treating N&V in patients receiving radiation to the brain, as it also reduces cerebral edema. It is administered orally, IM, or IV in the dose range of 8 mg to 40 mg (pediatric dose: 0.25–0.5 mg/kg).[74,75,76,77,78] Methylprednisolone is also administered orally, IM, or IV at doses and schedules that vary from 40 mg to 500 mg every 6 to 12 hours for up to 20 doses.[73,79]
Dexamethasone is also used orally for delayed N&V. Long-term corticosteroid use, however, is inappropriate and may cause substantial morbidity, including the following:
A study that examined chemotherapy in a group of patients with ovarian cancer found that short-term use of glucocorticoids as antiemetics had no negative effects on outcomes (e.g., overall survival or efficacy of chemotherapy).[80] As previously shown with metoclopramide, numerous studies have demonstrated that dexamethasone potentiates the antiemetic properties of 5-HT3 -blocking agents.[81,82,83,84,85] If given IV, dexamethasone should be given over 10 to 15 minutes, since rapid administration may cause sensations of generalized warmth, pharyngeal tingling or burning, or acute transient perineal and/or rectal pain.[77,86,87,88]
Prednisone and adrenocorticotropic hormone (ACTH) given concomitantly with other active antiemetic agents have also demonstrated efficacy against N&V caused by cisplatin-containing chemotherapy during the acute phase (within 24 hours after receiving chemotherapy).[89,90,91] In a double-blind, randomized study of metoclopramide and dexamethasone with or without 1 mg of ACTH, patients receiving ACTH prophylaxis for cisplatin-containing chemotherapy experienced a significantly decreased incidence and severity of delayed emesis for up to 72 hours after treatment.[91]
The plant Cannabis contains more than 60 different types of cannabinoids, or components that have physiologic activity. The most popular, and perhaps the most psychoactive, is delta-9-tetrahydrocannabinol (delta-9-THC).[92] There are two FDA-approved products for CINV:
With respect to CINV, Cannabis products probably target cannabinoid-1 (CB-1) and CB-2 receptors, which are in the central nervous system.[93] Another product, Sativex, a cannabidiol that is a buccal spray, is under investigation.[94,95]
Much of the research on this class of agent was conducted in the late 1970s and 1980s and compared Cannabis to older antiemetic agents that targeted the dopamine receptor, such as prochlorperazine (Compazine) and metoclopramide (Reglan).[92,96,97,98,99,100,101,102,103] This group of studies demonstrated that Cannabis was as effective for moderately emetogenic chemotherapy as dopaminergic antiemetics or was more effective than placebo.[92] Side effects of Cannabis products included euphoria, dizziness, dysphoria, hallucinations, and hypotension.[92] Despite earlier reports of efficacy, in at least one study, patients did not significantly prefer Cannabis agents because of the side effects.[96]
Research in nausea and vomiting since the 1990s has elucidated newer and more physiologic targets, namely 5-HT3 and NK-1 receptors. Subsequently, 5-HT3 and NK-1 receptor antagonists have become standard prophylactic therapy for CINV. Studies investigating the role of Cannabis with these newer agents are few; therefore, limited conclusions can be drawn. In published trials, however, Cannabis has not demonstrated more efficacy than 5-HT3 receptor antagonists, and synergistic or additive effects have not been fully investigated.[93,104,105]
In summary, the place of Cannabis in today's arsenal of antiemetics for the prevention and treatment of CINV is not known. Discussions with patients about its use should include responses to available agents, known side effects of Cannabis, and an assessment of the risks versus benefits of this therapy.[106]
For a broader discussion of the issues surrounding Cannabis use, refer to the PDQ summary on Cannabis and Cannabinoids.
Benzodiazepines such as lorazepam, midazolam, and alprazolam have become recognized as valuable adjuncts in the prevention and treatment of anxiety and the symptoms of anticipatory nausea and vomiting (ANV) associated with chemotherapy, especially with the highly emetogenic regimens given to children.[107,108,109] Benzodiazepines have not demonstrated intrinsic antiemetic activity as single agents. Therefore, their place in antiemetic prophylaxis and treatment is adjunctive to other antiemetic agents.[110] Benzodiazepines presumably act on higher CNS structures, the brainstem, and spinal cord, and they produce anxiolytic, sedative, and anterograde amnesic effects. In addition, they markedly decrease the severity of EPRs, especially akathisia, associated with dopaminergic receptor antagonist antiemetics.
Lorazepam may be administered orally, IM, IV, and sublingually. Dosages range from 0.5 to 3 mg (alternatively, 0.025–0.05 mg/kg, or 1.5 mg/m2, but ≤4 mg per dose) in adults and 0.03 to 0.05 mg/kg in children every 6 to 12 hours.[111][Level of evidence: I][107,112,113] Midazolam produces mild-to-marked sedation for 1 to 4.5 hours at doses equal to 0.04 mg/kg given IV over 3 to 5 minutes.[114,115] Alprazolam has been shown to be effective when given in combination with metoclopramide and methylprednisolone.[116]
The adverse effects of lorazepam include the following:[117]
Olanzapine is an antipsychotic in the thienobenzodiazepine drug class that blocks multiple neurotransmitters: dopamine at D1, D2, D3, and D4 brain receptors; serotonin at 5-HT2a, 5-HT2c, 5-HT3, and 5-HT6 receptors; catecholamines at alpha-1 adrenergic receptors; acetylcholine at muscarinic receptors; and histamine at H1 receptors.[118] Common side effects include the following:[119,120,121]
Olanzapine has also been associated with increased risk of hyperlipidemia, hyperglycemia, new-onset diabetes and, in rare cases, diabetic ketoacidosis.[119,121,122] Olanzapine should be used with caution in elderly patients; it has been associated with increased risk of death and increased incidence of cerebrovascular adverse events in patients with dementia-related psychosis and carries a boxed warning to that effect.[119] Olanzapine's activity at multiple receptors, particularly at the D2 and 5-HT3 receptors that appear to be involved in N&V, suggests that it may have significant antiemetic properties.
There have been case reports on the use of olanzapine as an antiemetic.[123][Level of evidence: II];[124,125,126,127] These case reports prompted a phase I study in which olanzapine was used for the prevention of delayed emesis in cancer patients receiving their first cycle of chemotherapy consisting of cyclophosphamide, doxorubicin, cisplatin, and/or irinotecan.[128] The protocol was completed by 15 patients, and no grade 4 toxicities were seen. The maximum tolerated dose was 5 mg/day for 2 days prior to chemotherapy and 10 mg/day for 7 days postchemotherapy. On the basis of these data, olanzapine appeared to be a safe and effective agent for the prevention of delayed emesis in chemotherapy-naive cancer patients receiving cyclophosphamide, doxorubicin, cisplatin, and/or irinotecan.
Using the maximum tolerated dose of olanzapine in the phase I trial, a phase II trial was performed for the prevention of CINV in patients receiving their first course of either highly emetogenic or moderately emetogenic chemotherapy. Olanzapine was added to granisetron and dexamethasone prechemotherapy and to dexamethasone postchemotherapy. CR (no emesis, no rescue) was 100% for the acute period (24 hours postchemotherapy), 80% for the delayed period (days 2–5 postchemotherapy), and 80% for the overall period (0–120 hours postchemotherapy) in ten patients receiving highly emetogenic chemotherapy (cisplatin, ≥70 mg/m2). CR was also 100% for the acute period, 85% for the delayed period, and 85% for the overall period in 20 patients receiving moderately emetogenic chemotherapy (doxorubicin, ≥50 mg/m2). Nausea was very well controlled in the patients receiving highly emetogenic chemotherapy, with no patient having nausea (0 on a scale of 0–10, M. D. Anderson Symptom Inventory) in the acute or delayed periods. Nausea was also well controlled in patients receiving moderately emetogenic chemotherapy, with no nausea in 85% of patients in the acute period and in 65% of patients in the delayed and overall periods. There were no grade 3 or 4 toxicities. On the basis of these data, olanzapine appeared to be safe (sedation was the only dose-limiting toxicity) and effective in controlling acute and delayed CINV in patients receiving highly emetogenic and moderately emetogenic chemotherapy.[129][Level of evidence: II]
Subsequent studies have shown the effectiveness of olanzapine as an antiemetic. Olanzapine combined with a single dose of dexamethasone and a single dose of palonosetron was very effective in controlling acute and delayed CINV in patients receiving either moderately emetogenic chemotherapy or highly emetogenic chemotherapy.[130] A large end study [131][Level of evidence: I] demonstrated that in patients receiving either highly emetogenic chemotherapy or moderately emetogenic chemotherapy, the addition of olanzapine to azasetron and dexamethasone improved the CR of delayed CINV.
Other Pharmacologic Agents
The antiemetic effect of ginger powder (Zingiber officinale) was explored in a double-blind, placebo-controlled, randomized trial among 32 children and young adults, aged 8 to 21 years, with newly diagnosed bone sarcomas.[132] Cycles of chemotherapy were randomly assigned to ginger powder (1,000 to 2,000 mg per day) or placebo on days 1 to 3 of treatment. Patients were allowed to receive the standard antiemetic medications ondansetron and dexamethasone. The primary endpoint was the incidence and severity of acute N&V (occurring ≤24 hours from the start of chemotherapy) and delayed N&V (occurring >24 hours after completion of chemotherapy).
The authors reported a reduction in the incidence of moderate to severe acute nausea in the experimental arm (55.6 % of cycles), compared with the placebo arm (93.3% of cycles) (P = .003). Decreased incidence of moderate to severe vomiting was found in the experimental arm (33.3%), compared with the placebo arm (76.7%) (P = .002). The authors also reported decreased incidence of moderate to severe delayed nausea (P < .001) and vomiting (P = .022) in the experimental arm, compared with placebo. No adverse events were reported.[132]
Although these results are encouraging, the study was limited by a small sample size, lack of stratification by antiemetic regimen, and no intra- or interindividual reporting. Subsequent studies are needed to confirm these preliminary findings.
Management of CINV
Current guidelines [133,134] recommend that prechemotherapy management of CINV be based on the emetogenic potential of the chemotherapy agent(s) selected. For patients receiving regimens with high emetogenic potential, the combination of a 5-HT3 receptor antagonist, aprepitant, and dexamethasone is recommended prechemotherapy; lorazepam may also be used. Aprepitant and dexamethasone are recommended postchemotherapy for the prevention of delayed emesis.
For patients receiving moderately emetogenic chemotherapy, the combination of a 5-HT3 receptor antagonist and dexamethasone should be used prechemotherapy, with or without lorazepam. Patients receiving the combination of an anthracycline and cyclophosphamide and select patients receiving certain other agents of moderate emetic risk, such as cisplatin (<50 mg/m2) or doxorubicin, should also receive aprepitant. Postchemotherapy, a 5-HT3 receptor antagonist, dexamethasone, or both are recommended for the prevention of delayed emesis.
For regimens with low emetogenic potential, dexamethasone is recommended with or without lorazepam. For regimens with minimal emetogenic risk, no prophylaxis is recommended.[133,134]
Antiemetic guidelines [133,134] have included the available oral 5-HT3 receptor antagonists as optional therapy for the prevention of delayed emesis, but the level of evidence supporting this practice is low.[48]
Clinicians and other health care professionals who are involved in administering chemotherapy should be aware that studies have strongly suggested that patients experience more acute and delayed CINV than is perceived by practitioners.[48,135,136] One study suggested that patients who are highly expectant of experiencing nausea appear to experience more postchemotherapy nausea.[137] In addition, the current and new agents have been used as prophylaxis for acute and delayed CINV and have not been studied for use in established CINV.[48,49] One study reported the effective use of IV palonosetron and dexamethasone for the prevention of CINV in patients receiving multiple-day chemotherapy.[138]
Pre- and postchemotherapy recommendations by emetogenic potential are summarized in Table 3.
Current Clinical Trials
Check NCI's list of cancer clinical trials for U.S. supportive and palliative care trials about nausea and vomiting therapy that are now accepting participants. The list of trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
Nausea and vomiting (emesis) (N&V) are common symptoms in patients with advanced cancer, occurring in approximately 21% to 68% of these patients.[1,2] The underlying pathophysiology and treatment differs somewhat from nausea related to radiation treatment or chemotherapy. Chronic nausea can significantly impair a patient's quality of life.
Pathophysiology and Causes
Chronic nausea in the advanced cancer setting is often multifactorial in origin.[1,2,3] Medications, including some that are frequently prescribed in this setting—such as opioids, nonsteroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitor (SSRI) antidepressants—may be responsible.
In the case of opioids, nausea frequently resolves spontaneously a few days after initiation of treatment. In some cases, however, it may persist. Nausea resulting from the accumulation of active opioid metabolites (morphine-6-glucuronide) has been described,[4] and patients with impaired renal function may be at increased risk. Opioids invariably produce constipation if prophylactic measures are not taken (namely, the use of a regular laxative regimen), and constipation is one of the most common causes of nausea in patients with advanced cancer.[5,6,7,8]
Opioid-induced gastrointestinal (GI) motility problems may compound the problem of diminished GI motility that many patients experience as part of the anorexia-cachexia syndrome of advanced cancer. The autonomic dysfunction that often accompanies this syndrome results in decreased GI motility, early satiety, and chronic nausea.[9,10,11] Other causes of chronic nausea in these patients include the following:[12]
Nausea, like many other symptoms, may have psychological undercurrents that either exacerbate or induce chronic nausea.
A comprehensive history that includes determining the frequency and effectiveness of bowel movements and laxative therapy is essential. Concurrent medications should be reviewed, and the frequency and nature of N&V should be documented. Examination should attempt to exclude bowel obstruction, fecal impaction, dehydration, and raised intracranial pressure. History and physical examination are poor at determining the extent of constipation.[5] A plain flat-plate x-ray of the abdomen can be very useful to this end.[13] Surgical x-ray views of the abdomen may be helpful if a bowel obstruction is suspected. Investigations to determine blood levels of electrolytes, calcium, and renal parameters may also be helpful.
Management centers on identifying the underlying causes, addressing these when possible, and controlling the symptoms.[1,2] A basic working knowledge of the emetic pathways and identification of possible underlying causes should guide antiemetic selection.
Multiple antiemetic regimens have been proposed for the management of chronic nausea in the advanced cancer setting. Prospective studies comparing one regimen with another are lacking. Metoclopramide or domperidone are generally recommended as first-line agents because they improve GI motility and act on the chemoreceptor trigger zone (as a result of their antidopaminergic properties).[14] Metoclopramide can be administered orally or parenterally (subcutaneously or intravenously [IV]) at doses of 10 mg, 4 times a day, or on an every-4-hour basis, depending on the severity of the nausea. Rescue doses should also be ordered on an as-needed basis to manage the episodic worsening of nausea that may occur.
Extrapyramidal-related adverse effects are a potential complication of these medications but appear to occur infrequently. Domperidone, which is currently unavailable in the United States, is associated with fewer of these adverse effects. Unfortunately, this drug is not available in a parenteral formulation. Dimenhydrinate (Dramamine) or antihistamine agents may be used if a complete bowel obstruction is suspected (in which case prokinetic agents are contraindicated) or if patients are intolerant to other antiemetic agents. Haloperidol, a potent antidopamine agent, may be considered if bowel obstruction is the underlying problem.[15]
The phenothiazine drugs are sometimes used,[16][Level of evidence: II] but the high incidence of adverse effects such as somnolence and anticholinergic-related effects (orthostatic hypotension and confusion) limit their role. Chlorpromazine has modest antiemetic activity but a high incidence of sedation, postural hypotension, and anticholinergic adverse effects, while piperazine derivatives such as prochlorperazine are stronger antiemetics but cause more extrapyramidal side effects. Hyoscine butylbromide, on the other hand, can be useful for patients experiencing colic from complete bowel obstruction.
A continuous parenteral infusion of metoclopramide, at doses of 60 to 120 mg/day, may be helpful for patients with intractable chronic nausea.[17] The judicious use of corticosteroids such as dexamethasone in selected patients may be useful in conjunction with a more traditional antiemetic, although one study has suggested that dexamethasone was not better than placebo in patients who were not controlled with metoclopramide.[18][Level of evidence: I] The exact mechanism of action and the optimal dose of corticosteroids for this indication are not known.
In contrast to radiation therapy–induced nausea or chemotherapy-induced nausea, the role of 5-HT3 receptor antagonists (such as ondansetron) is not clear in the setting of chronic nausea in advanced cancer, but it appears to be limited to a small number of highly selected cases, specifically those that have failed all other treatments.[19]
A case series study has suggested an antiemetic effect for olanzapine (an atypical antipsychotic) in advanced cancer patients being treated with opioids who are complaining of apparent opiate-induced nausea. However, further study and comparison with standard management are required.[20]
The management of constipation can be divided into general interventions and therapeutic measures.[21] The general interventions include the prevention of constipation by initiating regular laxative regimens, particularly in patients on opioid treatment, and where possible, the elimination of medical factors that may be contributing to constipation (e.g., discontinuation of nonessential constipating drugs). Prophylactic laxative regimens may consist of stool softeners such as docusate and bowel stimulants such as sennosides. Occasionally lactulose may be added. If necessary, a hyperosmolar laxative such as lactulose or polyethylene glycol may be added.[22] These regimens should be reviewed on a regular basis and their doses adjusted, depending on the regularity of bowel movements. High-fiber diets, while generally recommended, may be difficult for patients with very advanced cancer. Bulk agents such as psyllium or cellulose are unsuitable for patients with advanced cancer because the high fluid intake required with these agents is often intolerable to patients. (Refer to the PDQ summaries on Gastrointestinal Complications and Pain for more information on the management of constipation caused by opioids.)
Therapeutic interventions for the routine management of constipation may be administered orally or rectally, as follows:
Once the constipation is cleared, the background laxative regimen (e.g., sennoside and docusate) should be reviewed with a view to optimizing it. The action of the saline and magnesium salts is not physiological, and regular ongoing administration should be avoided. Saline laxatives should be used with caution in patients with renal impairment or cardiac failure. Mineral oil enemas are used occasionally and act as both lubricants and stool softeners; however, they may interfere with the absorption of fat-soluble vitamins, and there is a risk of lipoid pneumonia in debilitated patients. The use of enemas and rectal suppositories is usually limited to the acute short-term management of more severe episodes of constipation. However, patients with neurogenic bowel problems (e.g., patients with irreversible spinal cord compression) often require regular ongoing treatment with suppositories as part of their bowel care. The rectal route is contraindicated in patients with mucosal integrity/bowel-wall compromise. (Refer to the PDQ summary on Gastrointestinal Complications for more information.)
There have been no adequate comparative studies between the various laxatives to make evidence-based recommendations on which laxative regimen is optimal. Patients with advanced cancer are at risk of becoming constipated and generally require a regular bowel regimen, even if they are not eating. This need is amplified when they are on opioid treatment. On occasion, patients may present with a refractory narcotic bowel syndrome despite aggressive bowel care. Methylnaltrexone, a quaternary derivative of naltrexone, is an opioid antagonist that does not cross the blood-brain barrier. Preliminary studies suggest that it may be effective when given subcutaneously in the management of opioid-associated constipation without causing opioid withdrawal.[23][Level of evidence: I];[24,25] Methylnaltrexone should be avoided in cases of bowel obstruction and suspected bowel obstruction. This has not been studied in children.
Malignant Bowel Obstruction
The initial approach to assessing and managing malignant bowel obstruction in the advanced cancer patient involves determining whether the obstruction is reversible and whether the obstruction is partial or complete.[26,27,28] Suitability for surgery such as resection or intestinal bypassing should be assessed. Several medical options are available to improve the comfort of patients with inoperable bowel obstructions.[29,30] Less aggressive surgical procedures such as the insertion of a venting gastrostomy tube can provide considerable relief. When the obstruction is complete and irreversible, the creation of ostomies may also provide relief. Nasogastric tubes may be used temporarily until the obstruction resolves; however, when the obstruction is irreversible, other options such as the insertion of a gastrostomy tube should be considered.
Antiemetic agents with prokinetic properties are relatively contraindicated in the presence of a complete obstruction, and alternative agents such as an antihistamine or haloperidol may be required. Clinical experience suggests that corticosteroids (e.g., dexamethasone at a starting dose of 6–10 mg subcutaneously, 3–4 times a day) may be useful for malignant bowel obstruction.[26,27] The optimal dose and duration of treatment has not been clarified.
Hydration and drugs such as opioids and antiemetics should be administered via routes other than the oral route. The subcutaneous route can be very convenient and effective for both hydration and opioid administration. This route is as effective as IV administration, is less invasive, and requires less maintenance than the IV route. Octreotide, a somatostatin analog, can be useful at doses of 100 µg to 200 µg subcutaneously, 3 times a day, for refractory obstruction.[26,27,31] In the United States, octreotide is often administered as a continuous infusion. If the obstruction causes severe colic, hyoscine butylbromide may be considered. The use of colonic endoluminal stenting devices in selected patients is gaining increasing attention.[32,33]
Nonpharmacologic strategies are also used to manage nausea and vomiting (emesis). These include the following:
Guided imagery, hypnosis, and systematic desensitization as means to progressive muscle relaxation have been the most frequently studied treatments for anticipatory nausea and vomiting (ANV) and are the recommended treatments for this classically conditioned response. (Refer to the Treatment of ANV section of this summary for more information.)
Patients receiving radiation to the gastrointestinal (GI) tract or brain have the greatest potential for nausea and vomiting (emesis) (N&V) as side effects. Because cells of the GI tract are dividing quickly, they are quite sensitive to radiation therapy. Radiation to the brain is believed to stimulate the brain's vomiting center or chemoreceptor trigger zone. Similar to chemotherapy, radiation dose factors also play a role in determining the possible occurrence of N&V. In general, the higher the daily fractional dose and the greater the amount of tissue that is irradiated, the higher the potential for N&V. In addition, the larger the amount of GI tract irradiated (particularly for fields that include the small intestine and stomach), the higher the potential for N&V. Total-body irradiation before bone marrow transplant, for example, has a high probability of inducing N&V as acute side effects.
N&V from radiation may be acute and self-limiting, usually occurring 30 minutes to several hours after treatment. Patients report that symptoms improve on days that they are not being treated. There are also cumulative effects that may occur in patients receiving radiation therapy to the GI tract.[1]
Complete control rates with 5-HT3 receptor antagonists for total-body irradiation vary from 50% to 90%.[2,3,4] The role of corticosteroids in combination with 5-HT3 receptor antagonists has not been studied.
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Prevention of Acute/Delayed Nausea and Vomiting (Emesis)
Added text about a randomized phase III trial evaluating the use of aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone (cited Albany et al. as reference 64).
This summary is written and maintained by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of nausea and vomiting (emesis) (N&V). It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."
The preferred citation for this PDQ summary is:
National Cancer Institute: PDQ® Nausea and Vomiting. Bethesda, MD: National Cancer Institute. Date last modified <MM/DD/YYYY>. Available at: http://cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional. Accessed <MM/DD/YYYY>.
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page.
Contact Us
More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site's Contact Form.
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).
Last Revised: 2012-10-26
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.


text:
Panola College - Distance Learning
Panola College offers three types of eLearning Classes.
1. Internet Courses
There are usually no classroom sessions to attend. You, the student, take a very active
role in your learning. You are expected to participate with other students in a variety
of activities, turn your assignments in on time, and read a great deal of material.
All online courses are required to have at least two proctored exams at a testing
center approved by the instructor.
2. Online Hybrid Courses
Fifty percent or more of your time will be spent online. The remainder will be in class. Most of your course content will be available on the web and class time will be used to expand your understanding of what you have learned online. This method is becoming most popular with students and instructors because it combines the best of the online and face-to-face worlds.
3. Interactive Television (ITV) Courses
ITV, or Interactive Television, courses are synchronous because everyone meets at the same time although they are in different physical locations. ITV classrooms are located in Carthage, Center, Marshall, and area high schools. If you are not in the ITV classroom with your instructor, you will have a facilitator to assist students and to maintain equipment. ITV classes may be hybrid.

subset: commoncrawl


text:
U2 frontman Bono remembers Nelson Mandela the way many others did: an anti-apartheid, anti-poverty leader who became South Africa's first democratically elected President.
But some of the most intriguing insights in Bono's Time.com tribute to Mandela had nothing to do with him as a leader, but rather what he was like as a person.
"He had humor and humility in his bearing," Bono wrote. "And he was smarter and funnier than the parade of world leaders who flocked to see him."
Mandela's death on Thursday has prompted an outpouring of reactions from world leaders, celebrities and other prominent figures and some of the most heartfelt tributes emerging in the wake of his passing are offering unique perspective into the former South African president's electrifying life.
Mandela damaged his tear ducts while working in the limestone mines, which left him unable to cry, Bono wrote. "For all this man's farsightedness and vision, he could not produce tears in a moment of self-doubt or grief." Mandela had surgery in 1994 to fix his eye, according to Bono.
Here are six other powerful tributes:
Actor Morgan Freeman played up Mandela's "wisdom, patience and compassion" in a tribute that was also published Thursday on Time.com. Freeman said he shared a 20-year friendship with Mandela.
"I got to walk with him, talk with him, hold his hand and get to know one of the greatest men who ever lived," Freeman wrote.
Freeman went on to play Mandela in "Invictus," the 2009 film inspired by rugby player Francois Pienaar, who led the South African national rugby team to the win the World Cup in 1995. Rugby was a symbol of racist white rule for many black people in South Africa, but Mandela saw sports as unifier for his "Rainbow Nation."
Freeman said Mandela's reaction to the movie was "consistent with the true content of his character."
"His only comment after we first screened the movie for him was a humble, 'Now perhaps people will remember me.'" Freeman wrote.
Pienaar, the rugby player portrayed by Matt Damon in the film, recounted his first meeting with Mandela in an interview published on Friday by the Global Post. He said that what he heard first was Mandela's "booming voice," but what he remembers most was the president's "sense of warmth."
"I felt safe," Peinaar said. "I felt like I was in the presence of a very, very wise person."
President Barack Obama also understood the effect Mandela had on people. He said in a speech on Thursday that he drew inspiration from Mandela's work to affect change through politics. But it was Mandela's human side, the president said, that made him effective.
"The fact that he did it all with grace and good humor, and an ability to acknowledge his own imperfections, only makes the man that much more remarkable," Obama said. "As he once said, 'I am not a saint, unless you think of a saint as a sinner who keeps on trying.'"
Oprah Winfrey, meanwhile, planned to re-air on OWN Sunday an interview she conducted with Mandela in 2000.
Spending time with him was like "sitting with grace and majesty," Winfrey said in a statement on her website. But Mandela, "always loved to tell a good joke."
New York Times journalist Suzanne Daley, the paper's Johannesburg bureau chief from 1995 to 1999, remembered Mandela as "quite a dandy" who fussed over his appearance and enjoyed flirting with women.
"He always managed to talk to the women wherever he went," Daley wrote in the Times. "Young or old. He would literally get a sparkle in his eyes when there was a pretty girl around. Even when he didn't seem to be looking, he took notice. He liked to tease."
Next week's cover of the "New Yorker" magazine will hone in on a different side of Mandela, that of a freedom fighter. It will feature a drawing of a young Mandela with his fist raised. Artist Kadir Nelson said he wanted to make a "simple and bold statement about Mandela and his life as a freedom fighter."
"The raised fist and the simple, stark palette reminded me of posters and anti-apartheid imagery of the nineteen-eighties," Nelson said. "This painting is a tribute to the struggle for freedom from all forms of discrimination, and Nelson's very prominent role as a leader in the anti-apartheid movement."


text:
Wonderfully light semi-sweet wine. Made with Wisconsin Foch grapes pressed from the skins & slowly fermented making this beautiful blush wine. Detect the flavors of strawberry and cherry. Very clean! Enjoy with a meal or by itself. Suggest serve chilled.
Due to Wisconsin state laws on shipping wine, we have to ask that you fill out your birthdate . This also includes the birthdate of the recipient if you are sending it to someone other than yourself.
Please enter fileds below as MM/DD/YYYY or N/A
Not logged in
Home |
About Us |
Event Calendar |
Shop Wine Online |
Product Search |
View Your Cart |
Order Status |
Order Tracking |
Gift Certificates |
Terms & Conditions |
Contact Us
WE WILL BE OPEN ON LABOR DAY, Monday 9/2 11am-3pm
Fridays 11am-4pm, Sat 10am-5pm, Sun 11am-2pm
Mon, Tues, Wed & Thurs please call for appt. 608-647-6600
We welcome you to visit us at Weggy Winery!
You may call 608-647-6600 to make an appointment to visit us at Weggy Winery Monday through Thursday and we will do our best to accomodate YOU!
© 2015 - 2019 Weggy Winery, All rights reserved.
Responsive / Mobile Websites, Website Design, Hosting & SEO by Page 1 SEO Design LLC


text:
Or Login using BecomeGorgeous
Please fill the form below and follow the further instructions.
You are about to receive a email from us please make sure to check your spam or junk folder and add our email [email protected] to your contact list.
Thank you!
The fact that we are all different allows much more room for diversity when it comes to fashion, style and even hair color, so one can opt for a look which underlines best his/her personality. Hair color plays a very important role when it comes to physical appearance this is why it is important to choose a hair color which suits your skin tone and personality best, so you can look amazing. Hair color can help enhance your natural beauty and there is a variety of cool hair color ideas to choose from. The evolution of the cosmetic industry ha... Read More


text:
Danica Patrick took a break from her busy schedule driving in Nascar and wishing she was a honey badger to star as a car thief in Miranda Lambert's new video "The Fastest Girl In Town."
Truth be told, Danica's role as a
wheelman wheelperson isn't bad. Watching the video isn't the cringe-worthy experience you might expect from a race car driver acting.
Though we are a little disturbed knowing she could get gigs like this all day and still pull fat sponsorship checks even if she comes in last place at every race when she graduates to the Sprint Cup next year.


text:
Best Investment to Pick for Today: March 05, 2018
Today's Pick is : WIN
Today's Forecast: Near Term Up
Learn More Info Here : https://goo.gl/VW6NkV
See Our Other Pick of the Days here: https://goo.gl/R2MPZV or watch our Channel here: https://goo.gl/oeVCjk
Missed the last pick? Don't worry, we have you covered. You can check our last post: https://www.arbitragebands.com/best-stock-pick-today-march-02-2018/ or take a look at our video on youtube here: https://youtu.be/Z5OMjSz2T8E
Instead of spending countless hours trying to pick the right stock, you can simply follow the math of Arbitrage Bands™. Each day Arbitrage Band will prepare a report for you on which stocks were winners for the day and which ones were losers for that day and what to expect for tomorrow. This type of information can help you make decisions that will give you the best chance of succeeding in the markets. Not only can this information help you invest your money in stocks that are more likely to succeed, it will also help you to avoid losses by showing you which stocks to avoid.
To learn more about Arbitrage Bands – Go here


text:
Q A local utility recently insisted that I provide a larger service entrance conductor than the Code seems to require.
The application is as follows: A new 10,000-sq.-ft. metal building was constructed for use only as a warehouse for storing pallets of equipment and parts. Sixteen 250W high-bay lights were installed on four 120V AC breakers. About 20 120-V AC receptacles were installed on about eight 20A breakers. Some bathroom lights, emergency and exit lights, and other small miscellaneous loads were installed. There are no significant motor loads, air conditioning or HVAC equipment. The total connected load on the main panelboard is estimated at about 12.0 KVA. Based on this, the connected load would be less than 15A per phase. A pad-mounted, utility transformer serves the new warehouse. This transformer is rated 75KVA, three-phase. The secondary is 480/277V AC, wye-connected. This transformer feeds a 400A, three-phase, four-wire panelboard with main lugs only through an underground conduit. A 100A breaker in the main panelboard feeds a 480/277V to 208/120V transformer and this transformer supplies a 208/120V panelboard for lighting and receptacles. A 200A spare breaker was installed in the main panelboard, but no load connected.
Paragraph 230-42 of the 1999 NEC deals with the required size and ratings of service entrance conductors. Subparagraph (a) states that the ampacity of the service entrance conductors before the application of any adjustment factors shall not be less than the sum of the non-continuous loads plus 125% of continuous loads. Assuming the loads to be 100% continuous, we say the NEC dictates service conductors have ampacity not less than 18A.
Article 240 deals with overcurrent protection. Paragraph 240-21(c) (4) deals specifically with protection for transformer secondary conductors. Paragraph 240-21(d) deals specifically with protection for service entrance conductors. We were unsure of whether to use (c) or (d), since the service entrance conductors are technically transformer secondary conductors. However, close reading seems to indicate these two sections have the same requirements. It appears the service entrance conductors may be considered protected by a grouping of no more than six breakers in the main panel, so long as the ampacity rating of the service entrance conductors exceeds the sum of the trip settings of all installed breakers. We believe this section requires that the service entrance conductors to have a minimum rating of not less than 300A and must therefore be a minimum size 350kcmil. We also believe that, based on this, the customer could have removed the 200A spare breaker from the main panel and size the service entrance conductors with a minimum rating of 100A, or a No. 2 AWG. The utility disagreed and insisted that the service entrance conductors be sized to carry the full load of the 400A panel. They required the customer to install 500kcmil service entrance conductors.
A The transformer secondary conductors are most likely service lateral conductors, so the overcurrent protection requirements are given in Sections 240-21(d) and 230-91. One to six devices may be used. The rating or combined ratings must not be less than the load calculated according to Article 220. In addition, according to Section 230-42, the ungrounded conductors must be at least as big as the required main disconnect. Based on your load, this minimum size would be 60A according to Section 230-79(d). Although you would be permitted to have conductors, a main disconnect, and an overcurrent device as small as 60A, 230-91 requires the overcurrent device to provide overload protection for the service conductors. According to 230-91, Exception No. 3, the two main devices you mention are permitted to exceed the rating of the service entrance conductors. Even though the disconnects are larger than the 60A size required, the conductors are still required by Section 230-42 to be only as big as the required size. The provision for future expansion without capacity for future expansion is not necessarily a Code violation, so the 60-A conductors could be terminated on the 400A main lugs. However, if there were only one main, perhaps a 400A molded-case circuit breaker in the panel, the conductors would have to be sized so they could be protected by the 400A device. The utility is not covered or necessarily bound by the Code requirements. They may have other rules. Many utilities require a minimum size conduit or a minimum size service. In your case, it appears that the utility does not want to serve a 400A panel unless the implied 400-A capacity is provided. This is well within their authority in most jurisdictions.


text:
Part Three: The commercial core at 53rd Street and Lake Park Avenue
By SUSAN OCONNOR DAVIS
It is no coincidence that the revival of Hyde Parks commercial core is centered at 53rd and Lake Park Avenue, an intersection that over the years has witnessed growth and decline, tragedy and renewal. Today on any weekend night there is a line out the door at Chipotle, valet parking is necessary if one drives to the hip new restaurant A10 and the smell of popcorn drifts out the door of a crowded Harper Theater. These welcome new enterprises can trace their roots back to the very foundation of the Hyde Park community.
Not long after a young lawyer named Paul Cornell arrived in Chicago in 1847, he made the acquaintance of the powerful Democratic senator from Illinois, Stephen A. Douglas. The advice Cornell received inspired his future, for Douglas envisioned a southward expansion of the city and encouraged slender, dark-haired young man to put all the money he could save into the land between the Chicago River and Lake Calumet.
Cornell began to familiarize himself with the area when his doctor advised that exercise and fresh air would help his health. The clean air found outside the crowded city was thought a common remedy for various ailments, and Cornell purchased a horse and often rode south out of the city. On the way he passed Douglas property at 31st Street and continued to what would later become 53rd Street there was a lakeside farm owned by the widow of early settler Nathan Watson.
Before long Cornell accumulated enough money to follow Douglass counsel, and purchased the 60-acre farm from Electa Watson in the late summer of 1853. Through a series of subsequent purchases, Cornell eventually accumulated 300 acres along the lakeshore. In a stroke of good luck and timing, the Illinois Central Railroad was extending their line from southern Illinois north to Chicago, and they soon made a deal with Cornell. He was no doubt elated at the prospect the railroad would greatly increase the value of his land. In return for Cornell deeding 60 of his 300 acres to the company, the Illinois Central agreed to open a station at 53rd Street and run daily passenger trains between the city and his holdings. The railroad depot ensured that this area at the heart of Cornells fledgling enterprise developed the most rapidly.
From the very beginning, Paul Cornell intended the development he christened Hyde Park to be a residential community. The only businesses permitted were located near the station and provided the most basic necessities for the residents. These were located just west of the intersection of the railroad tracks and 53rd, or Oak Street as it was known at the time. Cornells uncle Hassan Hopkins opened a small store; groceries and general merchandise were sold in this one-story structure that housed the local post office as well.
As the years passed, families who came to live in Cornells development gradually became less self-sufficient. Although they grew vegetables in backyard gardens and kept milk cows and other livestock, for the most part individuals became dependent on others for the necessities of life. Within 20 years of the communitys founding flats, shops and other business enterprises had opened and stretched west from the Illinois Central tracks at both 55th and 53rd Streets. The expanding support network for residents was evident as the number of food stores increased to 40 from six between 1883 and 1886, and included bakeries, fruit shops, and confectionary stores. There were cigar and tobacco shops, blacksmiths and livery stables, dressmakers and tailors. Doctors and dentists opened offices, and five real estate offices opened to serve the needs of prospective buyers. Liquor establishments proliferated; between 1877 and 1878, 49 saloon licenses were issued in the village, while just one was refused.
In the years before the turn of the century the commercial hub at 53rd Street had grown dramatically, and stood in contrast with the communitys otherwise suburban character. Surrounded by owner-occupied single-family frame houses, the center of Hyde Park offered housing in apartments constructed over street-level retail establishments, as well as various two-story business enterprises. Constructed around 1874 as Floods Hall, the three-story brick building on the southwest corner of 53rd and Lake streets was one of the first of the larger structures in Hyde Park and was part of a complex named for the owner Dr. James Ramsey Flood. A generous man, Flood resided just around the corner and donated his services to the Womens Hospital free of charge for 10 years, while holding regular office hours in Floods Block.
Various clubs for social events used Floods Hall, while the Hyde Park Herald was located on the second floor of another building on the block. The corner structure was later transformed for the Columbian Exposition the 75-room Hotel Helene offered European and American plans at the cost of $1.50 to $3 per day. But the building was an old one, and tragedy struck when a devastating and deadly fire broke out in the early morning hours on May 16, 1900. Flames could be seen throughout the neighborhood as the building was quickly engulfed by the ravaging blaze, and terrified guests leapt from the second and third stories to escape. The fire department concluded that they could do nothing to save the structure and were ill equipped to help those who jumped, many to their deaths. The national newspapers carried the story, often with lurid descriptions and predictions of death for the injured: The dead: Charlotte Peterson, dining room girl, found in her room burned to a crisp Seriously injured: Mrs. T.D. Allen, back broken and internally injured, jumped from three story window, will die…
In spite of lessons learned from the Chicago fire 30 years earlier, there was but a single exit, and neither the police nor the fire department was equipped with safety nets or ladders. Additionally, the June 3, 1900 Chicago Tribune noted safety conditions at the hotel were in a deplorable state of affairs, and the verdict read at court stated that had the laws and ordinances governing exits and fire escapes been enforced lives would not have been lost. City codes required that buildings over two stories have fire escapes.
As the fatal fire and the Hotel Helene faded from memory, a small bank and office building was erected in its place. Several years after the Sanborn map was updated, the Hyde Park Bank commissioned architect K. M. Vitzhum & Company to design the building on the site. When the 10-story classical revival structure was completed in 1928, it was one of Chicagos largest commercial buildings outside the Loop.
During the 20s it was evident that the era of Hyde Park as a suburban retreat was long over a wide range of apartment buildings filled block after block, resulting in a dense urban landscape. In 1889 there were 4,000 dwelling units in the area; between 1900 and 1920 another 6,000 were constructed. The center of Hyde Park had evolved into a largely working-class neighborhood with row houses, apartments and flats and small cottages, and was densely populated. As a result, the nearby commercial areas on 53rd and 55th streets accelerated their growth to meet the burgeoning demand, and the development of the streets here continued to reflect a mixed-use pattern of walk-up apartments with a variety of commercial spaces.
For quite a time 53rd Street was vibrant, enhanced with restaurants and motion picture theaters that were often built in combination with apartments and retail space. The air-conditioned Hyde Park Theater opened at 5312 Lake Street in December 1933 (now the Hyde Park Banks drive-in facility). Promising first-rate productions at neighborhood prices, the auditorium featured luxurious carpeting and royal velour seats. The next year B/G Sandwich Shop opened on the northeast corner, offering quality food at timely prices. They expanded after first opening the B/G Eating Inn at the Standard Oil Service Station on 50th Street between Harper Avenue and Lake Street. Victory Radio & Record was next door and according to the Herald was one of the most attractive places in all of the Hyde Park area. In the 40s the store featured beautiful fluorescent lights and soundproof record booths.
But time gradually took its toll on 53rd Street. Two world wars and a depression combined with changing demographics to produce widespread blight in these aging structures. There was an influx of residents to this area and apartments were cut unto kitchenettes to meet the demand, often without the necessary improvements to these older buildings. By the 50s it appeared Hyde Park would follow a trend that seemed inevitable: older neighborhoods grew more blighted, and were bulldozed as part of slum clearance programs. Although the larger community escaped that future, during land clearance and the massive urban renewal plan many of the structures near this intersection were torn down.
During urban renewal, the future of the surrounding neighborhood was dependent upon the various business centers renewal, where the different approaches to removing the blight are apparent. East 53rd Street retained a number of historic structures, while those on East 47th and 55th Streets were obliterated. Where older structures were retained, the street exhibits a completely different vibrancy. In her 1961 book The Life and Death of Great American Cities Jane Jacobs described it best, Cities need old buildings so badly it is probably impossible for vigorous streets and districts to grow without them.
Fifty years later it seems she had it right. The harshness of the recently erected structures is softened by the patina of the older buildings, creating a vibrant enclave that is a welcome addition to the Hyde Park community.
[nggallery id=84]


text:
Yeah, your flashlights are great, but let's hear about the other products. All I can say is.....wow! Your M73 Picatinny Rail Forend is the best out there. I did my shopping and compared all of the available hand guards out there. I cannot say enough about your "M" model. By far this is the best engineered device I've ever seen! When it arrived and I saw how the M73 mounted on the weapon, I was beside myself. I have never been so pleased with an "Attachment" than I am with your M73 Forend. The engineering of it has surpassed all out there. I am in no way showing favorites....This is just the truth. Yours attaches in such a way that it doesn't move one centimeter at all. The M73 is rock solid, lets the muzzle breathe, and with the lower front end (at the 'six' position) being a half inch longer, my bi-pod takes up less real estate on my weapon.I have bragged about your "M" series to all my "Black Rifle" buddies out there! Keep up the great work SureFire! Your very satisfied customer,
Mike C.
State College, PA
See the M73 forend:


text:
Carl Jacobi (July 10, 1908 - August 25, 1997) was an author. He wrote short stories in the horror, fantasy, science fiction, and crime genres for the pulp magazine market.
Jacobi was born in Minnesota in 1908 and lived there throughout his life. He attended the University of Minnesota from 1927 to 1930 where he began his writing career in campus magazines. Jacobi died on August 25, 1997.
Source: Wikipedia


text:
Willie Nelson, Sheryl Crow Jump on Board for Johnny Cash Tribute Show
To celebrate what would have been Johnny Cash's 80th birthday (Feb. 26), a host of country stars are banding together to bring a great tribute show to the legendary Austin City Limits TV show. The artists will be performing live at Austin's Moody Theatre with a special tribute show titled 'We Walk The Line: A Celebration of the Music of Johnny Cash.' Organizers of the show just announced today that the two newest additions to the already impressive April 20 lineup are Willie Nelson and Sheryl Crow.
This pair adds even more strength to an already strong lineup that includes Ronnie Dunn, Kenny Chesney, Lucinda Williams, Kris Kristofferson, Ray LaMontagne, Shooter Jennings, Jamey Johnson, Chris Cornell, John Hiatt, Carolina Chocolate Drops and Amy Lee. And the artists won't be going at it alone. They'll be supported by the musical stylings of a band made up of legendary talent including Buddy Miller, Kenny Aronoff, Ian McLagen and Greg Leisz -- all under the musical direction of Don Was.
"Having had the privilege of working with Johnny Cash on a Highwaymen project in 1995, I was able to experience firsthand the incredible spirit and musical gift that lived within Johnny," Was said in a press release. "We have an all-star line-up of incredible talent performing the songs that made Johnny a legend including fellow Highwaymen Kris and Willie. It will be an incredible evening of music of special combinations, duets and jams."
Not only will the event honor the Man in Black, it will be raising money for Charley's Fund, an organization that fights the fatal childhood disease Duchenne Muscular Dystrophy. Tickets for the live show are available for purchase on the Austin City Limits website.


text:
CHARLESTON, S.C. -- It proved tough to be a top seed at the Family Circle Cup this week.
Second-seeded Jelena Jankovic and No. 3-seeded Sara Errani were both upset Friday in the quarterfinals, leaving sixth-seeded Eugenie Bouchard as the lone top-10 seed left in the semifinals.
Jankovic fell to Bouchard, 6-3, 4-6, 6-,3 to start the round of eight before 17-year-old qualifier Belinda Bencic pulled off an even bigger shocker by eliminating Errani, a runner-up at the French Open in 2012.
Bencic, who had to win twice last weekend simply to make the field, took over in the final two sets for a 4-6, 6-2, 6-1 victory over the 26-year-old Italian. Bencic hadn't made it past the second round in two previous WTA events this year and wasn't expecting to advance to her first tour semifinals
"I was hoping for it and I was believing in me that it would come," she said. "Yeah, I'm just really happy it came this week."
Bencic will face either 12th-seeded Daniela Hantuchova or Jana Cepelova, who defeated world No. 1 Serena Williams on Tuesday night to start off a week of surprises at the Family Circle.
Errani looked confident and in control in the first set before getting overwhelmed by Bencic, who won 12 of the final 15 games. Errani talked to herself and even threw down her racket as Bencic's crisp shots clipped lines and moved out of reach.
Earlier, Bouchard rallied in the third set by winning five of the last six games to oust Jankovic, a past champion who came in ranked eighth in the world.
The 20-year-old Canadian reached the semifinals at a WTA tour event for the second time this season and fifth in her career.
On Saturday, she plays 14th-seeded Andrea Petkovic as she seeks her first title — something the sixth-seeded Bouchard thinks she's more than ready for.
"Every time I go into a tournament now and every match, I always believe I can win," she said.
Even when she falls behind, as happened in her past two matches. Bouchard trailed in the third set against Venus Williams on Thursday and Jankovic this time before rallying to victories.
"I feel confidence in myself," she said.
Petkovic topped ninth-seeded Lucie Safarova 6-3, 1-6, 6-1. The 26-year-old German, ranked 40th in the world, had struggled in recent events.
So Petkovic was pleased to shake off Safarova in the final set and advance to weekend play.
"I'm used to winning at least two, three matches and then losing to the top players, but it was a really tough few weeks for me in the past," she said. "So now I'm just really, really happy and kind of relieved."
Bouchard made it to the Australian Open semifinals this year, losing to eventual champion Li Na. In her only WTA final, she lost to Sam Stosur in Osaka in October.
Bouchard trailed 2-1 in the final set. She then dug in to win the next three games and take control. Her steady, strong groundstrokes wore down Jankovic.
"It was the third set and your concentration goes down a little bit if you're getting tired," Jankovic said. "It was so close. It could have went either way, if I was a little bit tougher out there and played certain points a little smarter."
The two also met in the quarterfinals last year, and Jankovic won 6-2, 6-1. Bouchard was ranked No. 114 then, but she's 20th now.
"Well, I didn't want it to be Groundhog Day today, for sure," Bouchard said. "Same tournament, same round, same opponent."
Not the same result.


text:
Welcome to the Quilting Board!
Members' photos of their quilting spaces. Share your ideas or ask advice about making the most of your space, work surfaces, and storage units.
Use this control to limit the display of threads to those newer than the specified time frame.
Allows you to choose the data by which the thread list will be sorted.
Order threads in...
Note: when sorting by date, 'descending order' will show the newest results first.
Forum Rules


text:
Also Known As
- T. J. Wilkinson
Game Credits
|The Hacker (1985)
Developer Biography
There is no biography on file for this developer.
[add bio]
If you have a portrait of this person, you can upload it to the MobyGames database.
Related Sites
There are no related websites on file for this developer. If you know of any related websites for the person, please consider contributing them.